Harvard Bioscience (HBIO) Total Non-Current Liabilities (2010 - 2026)
Harvard Bioscience (HBIO) posted quarterly Total Non-Current Liabilities of $66.7 million for Q1 2026, up 5.03% year-over-year from $63.6 million in Q1 2025, and up 2.64% quarter-over-quarter from $65.0 million in Q4 2025.
Harvard Bioscience (HBIO) Total Non-Current Liabilities (2010 - 2026) Analysis & Trends
Harvard Bioscience (HBIO) has reported Total Non-Current Liabilities for 17 consecutive years, with $66.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Non-Current Liabilities rose 5.03% year-over-year to $66.7 million; the TTM figure through Mar 2026 stood at $66.7 million (up 5.03% YoY), while the FY2025 annual figure was $65.0 million, up 4.8% from the prior year.
- Total Non-Current Liabilities climbed to $66.7 million in Q1 2026 per HBIO's latest filing, from $65.0 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $81.1 million in Q1 2022 and bottomed at $60.1 million in Q2 2024.
- Historically, Total Non-Current Liabilities has averaged $67.0 million across 5 years, with a median of $64.6 million in 2023.
- Annual changes were most pronounced in 2022 — Total Non-Current Liabilities advanced 13.73% — and 2023, when it retreated 14.07%.
- Harvard Bioscience's Total Non-Current Liabilities stood at $72.1 million in 2022, then dropped by 12.92% to $62.8 million in 2023, then decreased by 1.22% to $62.0 million in 2024, then gained by 4.8% to $65.0 million in 2025, then gained by 2.64% to $66.7 million in 2026.
- Business Quant data shows HBIO's Total Non-Current Liabilities at $66.7 million in Q1 2026, $65.0 million in Q4 2025, and $62.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 134.13 Bn | 128.91 Bn | 1.96 Bn | 1.92 Bn |
| 2 | Becton Dickinson | 52.76 Bn | 51.90 Bn | 2.32 Bn | 48.34 Bn |
| 3 | Alcon | 35.81 Bn | 34.46 Bn | 1.68 Bn | 6.34 Bn |
| 4 | Resmed | 33.72 Bn | 32.25 Bn | 861.22 Mn | 985.45 Mn |
| 5 | Medline | 29.38 Bn | 26.70 Bn | 2.22 Bn | 17.56 Bn |
| 6 | West Pharmaceutical Services | 25.00 Bn | 24.57 Bn | 329.20 Mn | 996.30 Mn |
| 7 | Solventum | 15.46 Bn | 15.06 Bn | 1.29 Bn | 8.96 Bn |
| 8 | Cooper Companies | 14.88 Bn | 14.74 Bn | 735.40 Mn | 3.98 Bn |
| 9 | Baxter International | 13.58 Bn | 11.43 Bn | 1.03 Bn | 12.41 Bn |
| 10 | Harvard Bioscience | 33.45 Mn | 26.94 Mn | 12.63 Mn | 67.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 67.71 Mn |
| Mar 31, 2026 | 66.75 Mn |
| Dec 31, 2025 | 65.03 Mn |
| Sep 30, 2025 | 62.46 Mn |
| Jun 30, 2025 | 62.93 Mn |
| Mar 31, 2025 | 63.55 Mn |
| Dec 31, 2024 | 62.05 Mn |
| Sep 30, 2024 | 64.42 Mn |
| Jun 30, 2024 | 60.06 Mn |
| Mar 31, 2024 | 62.90 Mn |
| Dec 31, 2023 | 62.82 Mn |
| Sep 30, 2023 | 64.56 Mn |
| Jun 30, 2023 | 66.47 Mn |
| Mar 31, 2023 | 69.78 Mn |
| Dec 31, 2022 | 72.13 Mn |
| Sep 30, 2022 | 74.61 Mn |
| Jun 30, 2022 | 77.35 Mn |
| Mar 31, 2022 | 81.07 Mn |
| Dec 31, 2021 | 78.46 Mn |
| Sep 30, 2021 | 74.51 Mn |